$PLRX
PLIANT THERAPEUTICS, INC.

2020 Form 10-K Financial Statement

#000156459021013589 Filed on March 16, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $41.82M $57.05M
YoY Change -26.7%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.27M $10.93M
YoY Change 58.01% 68.15%
% of Gross Profit
Research & Development $66.19M $47.35M
YoY Change 39.79% 93.91%
% of Gross Profit
Depreciation & Amortization $1.300M $570.0K $1.100M
YoY Change 18.18% 3.64% 64.18%
% of Gross Profit
Operating Expenses $83.46M $58.28M
YoY Change 43.2% 88.5%
Operating Profit -$41.65M -$1.231M
YoY Change 3283.02%
Interest Expense $480.0K $820.0K
YoY Change -41.46% 18.84%
% of Operating Profit
Other Income/Expense, Net -$370.0K -$220.0K
YoY Change 68.18% 340.0%
Pretax Income $41.50M $600.0K
YoY Change 6816.67% -101.98%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings -$41.53M -$631.0K
YoY Change 6482.09% -97.92%
Net Earnings / Revenue -99.32% -1.11%
Basic Earnings Per Share -$1.95 -$4.22
Diluted Earnings Per Share -$1.95 -$4.22
COMMON SHARES
Basic Shares Outstanding 21.34M shares 1.623M shares
Diluted Shares Outstanding 21.34M shares 1.623M shares

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $276.9M $102.8M $102.8M
YoY Change 169.36% 68.8%
Cash & Equivalents $50.90M $85.81M $85.80M
Short-Term Investments $226.0M $17.00M $17.00M
Other Short-Term Assets $4.500M $1.700M $1.700M
YoY Change 164.71% 466.67%
Inventory
Prepaid Expenses
Receivables $9.300M $7.052M $7.100M
Other Receivables $100.0K $300.0K $300.0K
Total Short-Term Assets $290.8M $111.9M $111.9M
YoY Change 159.87% 81.36%
LONG-TERM ASSETS
Property, Plant & Equipment $4.300M $4.079M $4.100M
YoY Change 4.88% -4.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $3.085M $3.100M
YoY Change -83.87% 520.0%
Total Long-Term Assets $4.700M $7.164M $7.200M
YoY Change -34.72% 50.0%
TOTAL ASSETS
Total Short-Term Assets $290.8M $111.9M $111.9M
Total Long-Term Assets $4.700M $7.164M $7.200M
Total Assets $295.5M $119.1M $119.1M
YoY Change 148.11% 79.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.000M $1.250M $1.300M
YoY Change 53.85% -50.0%
Accrued Expenses $9.600M $6.922M $6.900M
YoY Change 39.13% 176.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.60M $8.172M $8.200M
YoY Change 41.46% 60.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $900.0K $912.0K $900.0K
YoY Change 0.0% 12.5%
Total Long-Term Liabilities $900.0K $912.0K $900.0K
YoY Change 0.0% 12.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.60M $8.172M $8.200M
Total Long-Term Liabilities $900.0K $912.0K $900.0K
Total Liabilities $12.50M $9.084M $9.100M
YoY Change 37.36% 54.24%
SHAREHOLDERS EQUITY
Retained Earnings -$76.30M
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $283.1M -$76.30M $110.0M
YoY Change
Total Liabilities & Shareholders Equity $295.5M $119.1M $119.1M
YoY Change 148.11% 79.1%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$41.53M -$631.0K
YoY Change 6482.09% -97.92%
Depreciation, Depletion And Amortization $1.300M $570.0K $1.100M
YoY Change 18.18% 3.64% 64.18%
Cash From Operating Activities -$37.27M $21.87M -$2.750M
YoY Change 1255.31% -205.45% -90.29%
INVESTING ACTIVITIES
Capital Expenditures $1.532M -$230.0K $964.0K
YoY Change 58.92% -83.92% -141.55%
Acquisitions
YoY Change
Other Investing Activities -$209.3M $4.800M -$16.97M
YoY Change 1133.53%
Cash From Investing Activities -$210.9M $4.570M -$17.93M
YoY Change 1075.99% -419.58% 672.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $213.2M 46.44M $45.54M
YoY Change 368.2% -31.58% -47.87%
NET CHANGE
Cash From Operating Activities -$37.27M 21.87M -$2.750M
Cash From Investing Activities -$210.9M 4.570M -$17.93M
Cash From Financing Activities $213.2M 46.44M $45.54M
Net Change In Cash -$34.93M 72.88M $24.86M
YoY Change -240.5% 59.47% -56.16%
FREE CASH FLOW
Cash From Operating Activities -$37.27M $21.87M -$2.750M
Capital Expenditures $1.532M -$230.0K $964.0K
Free Cash Flow -$38.80M $22.10M -$3.714M
YoY Change 944.78% -214.45% -85.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020Q2 dei Entity Public Float
EntityPublicFloat
855889147
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50882000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117828000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76295000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
0
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35738192
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020 dei Trading Symbol
TradingSymbol
PLRX
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity File Number
EntityFileNumber
001-39303
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4272481
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
260 Littlefield Avenue
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2020 dei City Area Code
CityAreaCode
650
CY2020 dei Local Phone Number
LocalPhoneNumber
481-6770
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50882000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85807000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
226012000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
16966000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9279000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7052000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
83000
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
333000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4498000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1742000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
290754000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
111900000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4321000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4079000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
451000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3085000
CY2020Q4 us-gaap Assets
Assets
295526000
CY2019Q4 us-gaap Assets
Assets
119064000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2023000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1250000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9576000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6922000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11599000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8172000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
866000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
912000
CY2020Q4 us-gaap Liabilities
Liabilities
12465000
CY2019Q4 us-gaap Liabilities
Liabilities
9084000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2020Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
3000
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
400918000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-32000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
442000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
283061000
CY2020 us-gaap Operating Expenses
OperatingExpenses
83462000
CY2019 us-gaap Operating Expenses
OperatingExpenses
58283000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
238294000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
11000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-41645000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-76295000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
295526000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119064000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
181000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35552795
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1846024
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35552795
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1846024
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41817000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57052000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66193000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47353000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17269000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10930000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-1231000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-41533000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-631000
CY2020 plrx Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock
AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock
0
CY2019 plrx Accretion To Redemption Value And Dividends On Redeemable Convertible Preferred Stock
AccretionToRedemptionValueAndDividendsOnRedeemableConvertiblePreferredStock
6225000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41533000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6856000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.95
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.22
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.95
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.22
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21344236
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1623358
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21344236
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1623358
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-31000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-31000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41564000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-632000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3895000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-71469000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
51713000
CY2020 plrx Accretion Of Short Term Investments
AccretionOfShortTermInvestments
0
CY2019 plrx Accretion Of Short Term Investments
AccretionOfShortTermInvestments
254000
CY2020 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-17000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
188000
CY2019 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
50000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37271000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2750000
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
322605000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
28000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
174000
CY2019 plrx Accretion To Redemption Value And Cumulative Dividend On Redeemable Convertible Preferred Stock
AccretionToRedemptionValueAndCumulativeDividendOnRedeemableConvertiblePreferredStock
6225000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1829000
CY2020 us-gaap Profit Loss
ProfitLoss
-41533000
CY2019 us-gaap Profit Loss
ProfitLoss
-631000
CY2020 us-gaap Depreciation
Depreciation
1310000
CY2019 us-gaap Depreciation
Depreciation
1113000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3895000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1829000
CY2020 plrx Other Losses
OtherLosses
266000
CY2019 plrx Other Losses
OtherLosses
0
CY2020 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-250000
CY2019 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-167000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2227000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7052000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2756000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1458000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
70000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-232000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
922000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1255000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2689000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4255000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
113271000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
35000000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1532000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
964000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-210866000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17931000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
150751000
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10000000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
52019000
CY2019 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
47947000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
442000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
174000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2582000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
213212000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45539000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34925000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24858000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85807000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60949000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
159000
CY2020 plrx Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting
ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting
11000
CY2019 plrx Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting
ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting
30000
CY2020 plrx Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
0
CY2019 plrx Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
230000
CY2020 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-31000
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.46%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, useful lives assigned to property and equipment, the fair values of common and redeemable convertible preferred stock, stock-based compensation expense, accruals for research and development costs, income taxes and uncertain tax positions. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.46%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. The Company invests in money market funds, treasury bill and notes, government notes and corporate debt securities. The Company limits its credit risk associated with its cash and cash equivalents by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. However, the Company had deposits in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limit of $250,000. The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base. During the year ended December 31, 2020, Novartis accounted for 100% of the Company&#8217;s revenue&#8212;related party and accounts receivable.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.46%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve several other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products, including those that may be developed or marketed by larger companies, securing and protecting intellectual property, strategic relationships and dependence on key individuals and sole source suppliers.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.46%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</p>
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 plrx Contractual Arrangements Cancellation Period
ContractualArrangementsCancellationPeriod
P30D
CY2020 plrx Debt Instrument Remaining Maturity Period At Date Of Purchase
DebtInstrumentRemainingMaturityPeriodAtDateOfPurchase
P3M
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7.15
CY2020Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.13986014
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2020Q4 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2019 plrx Amount Of Gross Receipts During Period
AmountOfGrossReceiptsDuringPeriod
5000000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2800000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
263729000
CY2020 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
15000
CY2020 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
47000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
263697000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
53568000
CY2019 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000
CY2019 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
2000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
53567000
CY2020Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2019Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27047000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16655000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
7617000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4949000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
291000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
130000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
474000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
247000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
266000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7809000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6267000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3488000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2188000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4542000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2971000
CY2020Q4 plrx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3274000
CY2019Q4 plrx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2624000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1675000
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1263000
CY2020Q4 plrx Deferred Rent And Leasehold Incentive Obligation Current
DeferredRentAndLeaseholdIncentiveObligationCurrent
85000
CY2019Q4 plrx Deferred Rent And Leasehold Incentive Obligation Current
DeferredRentAndLeaseholdIncentiveObligationCurrent
64000
CY2020Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
581000
CY2019Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
458000
CY2020Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
283000
CY2019Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
444000
CY2020Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
2000
CY2019Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
10000
CY2020 plrx Redeemable Convertible Preferred Stock
RedeemableConvertiblePreferredStock
Each holder of shares of Preferred Stock was entitled to the number of votes equal to the number of shares of common stock into which such shares could have been converted and had voting rights and powers equal to the voting rights and powers of the common stock, and except as provided by law or by other provisions of the Company’s Certificate of Incorporation, as amended, could have voted together with the common stock as a single class on an as-converted basis on all matters as to which holders of common stock have the right to vote.
CY2020 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
Shares of the Preferred Stock were convertible at any time at the option of the holder into such number of shares as is determined by dividing the original issuance price by the conversion price in effect at the time.
CY2020 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1399
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of shares of common stock are entitled to one vote for each share of common stock held at any meeting of stockholders and at the time of any written action in lieu of a meeting.
us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7338314
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20346844
CY2020Q4 plrx Share Based Compensation Number Of Restricted Stock Awards Not Purchased
ShareBasedCompensationNumberOfRestrictedStockAwardsNotPurchased
4195
CY2020Q4 plrx Share Based Compensation Restricted Stock Awards Weighted Average Grant Date Fair Value Not Purchased
ShareBasedCompensationRestrictedStockAwardsWeightedAverageGrantDateFairValueNotPurchased
0.08
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3895000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1829000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
41500000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
600000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q4 plrx Valuation Allowance As Percentage On Deferred Tax Assets
ValuationAllowanceAsPercentageOnDeferredTaxAssets
1.00
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.074
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.027
CY2020 plrx Effective Income Tax Rate Reconciliation General Business Tax Credits Federal
EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal
0.053
CY2019 plrx Effective Income Tax Rate Reconciliation General Business Tax Credits Federal
EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal
2.959
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.010
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.500
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Other
EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Other
EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
-0.024
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.326
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2.677
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13512000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
124000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
428000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
73000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
36123000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22178000
CY2020Q4 plrx Deferred Tax Liabilities Asset Basis
DeferredTaxLiabilitiesAssetBasis
124000
CY2019Q4 plrx Deferred Tax Liabilities Asset Basis
DeferredTaxLiabilitiesAssetBasis
110000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1689000
CY2020 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
The Company’s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years ended December 31, 2017 through December 31, 2020.
CY2020 plrx Income Tax Examination Number Of Examinations Pending
IncomeTaxExaminationNumberOfExaminationsPending
0
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20240000
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
558000
CY2019Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
139000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
682000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
249000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35441000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21929000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1355000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
855000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
513000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
570000
CY2020 plrx Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
139000
CY2019 plrx Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
-70000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2007000
CY2020 plrx Operating Lease Rent Expense And Common Area Maintenance Charges
OperatingLeaseRentExpenseAndCommonAreaMaintenanceCharges
2500000
CY2019 plrx Operating Lease Rent Expense And Common Area Maintenance Charges
OperatingLeaseRentExpenseAndCommonAreaMaintenanceCharges
2500000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2027000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2098000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2171000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2247000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1144000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9687000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2020 us-gaap Defined Contribution Plan Plan Name Extensible List
DefinedContributionPlanPlanNameExtensibleList
plrx:FourZeroOneKPlansMember
CY2019 us-gaap Defined Contribution Plan Plan Name Extensible List
DefinedContributionPlanPlanNameExtensibleList
plrx:FourZeroOneKPlansMember
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3124572
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20086140
CY2020 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
CY2019 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
-6225000

Files In Submission

Name View Source Status
0001564590-21-013589-index-headers.html Edgar Link pending
0001564590-21-013589-index.html Edgar Link pending
0001564590-21-013589.txt Edgar Link pending
0001564590-21-013589-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gya0qbprn4kn000001.jpg Edgar Link pending
gya0qbprn4kn000002.jpg Edgar Link pending
gya0qbprn4kn000003.jpg Edgar Link pending
gya0qbprn4kn000004.jpg Edgar Link pending
gya0qbprn4kn000005.jpg Edgar Link pending
gya0qbprn4kn000006.jpg Edgar Link pending
gya0qbprn4kn000007.jpg Edgar Link pending
gya0qbprn4kn000008.jpg Edgar Link pending
gya0qbprn4kn000009.jpg Edgar Link pending
gya0qbprn4kn000010.jpg Edgar Link pending
gya0qbprn4kn000011.jpg Edgar Link pending
gya0qbprn4kn000012.jpg Edgar Link pending
gya0qbprn4kn000013.jpg Edgar Link pending
gya0qbprn4kn000014.jpg Edgar Link pending
gya0qbprn4kn000015.jpg Edgar Link pending
gya0qbprn4kn000016.jpg Edgar Link pending
gya0qbprn4kn000017.jpg Edgar Link pending
gya0qbprn4kn000018.jpg Edgar Link pending
gya0qbprn4kn000019.jpg Edgar Link pending
gya0qbprn4kn000020.jpg Edgar Link pending
gya0qbprn4kn000021.jpg Edgar Link pending
gya0qbprn4kn000022.jpg Edgar Link pending
gya0qbprn4kn000023.jpg Edgar Link pending
gya0qbprn4kn000024.jpg Edgar Link pending
gya0qbprn4kn000025.jpg Edgar Link pending
gya0qbprn4kn000026.jpg Edgar Link pending
gya0qbprn4kn000027.jpg Edgar Link pending
gya0qbprn4kn000028.jpg Edgar Link pending
gya0qbprn4kn000029.jpg Edgar Link pending
gya0qbprn4kn000030.jpg Edgar Link pending
gya0qbprn4kn000031.jpg Edgar Link pending
gya0qbprn4kn000032.jpg Edgar Link pending
gya0qbprn4kn000033.jpg Edgar Link pending
gya0qbprn4kn000034.jpg Edgar Link pending
gya0qbprn4kn000035.jpg Edgar Link pending
gya0qbprn4kn000036.jpg Edgar Link pending
gya0qbprn4kn000037.jpg Edgar Link pending
gya0qbprn4kn000038.jpg Edgar Link pending
gya0qbprn4kn000039.jpg Edgar Link pending
gya0qbprn4kn000040.jpg Edgar Link pending
gya0qbprn4kn000041.jpg Edgar Link pending
gya0qbprn4kn000042.jpg Edgar Link pending
gya0qbprn4kn000043.jpg Edgar Link pending
gya0qbprn4kn000044.jpg Edgar Link pending
gya0qbprn4kn000045.jpg Edgar Link pending
gya0qbprn4kn000046.jpg Edgar Link pending
gya0qbprn4kn000047.jpg Edgar Link pending
gya0qbprn4kn000048.jpg Edgar Link pending
plrx-10k_20201231.htm Edgar Link pending
plrx-20201231.xml Edgar Link completed
plrx-20201231.xsd Edgar Link pending
plrx-20201231_cal.xml Edgar Link unprocessable
plrx-20201231_def.xml Edgar Link unprocessable
plrx-20201231_lab.xml Edgar Link unprocessable
plrx-20201231_pre.xml Edgar Link unprocessable
plrx-ex311_10.htm Edgar Link pending
plrx-ex312_8.htm Edgar Link pending
plrx-ex321_9.htm Edgar Link pending
plrx-ex43_1583.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending